Clinical trial
DTGM Fusion Protein in Treating Patients With Recurrent or Refractory Acute…
NCT00003840 · Wake Forest University Health Sciences, Other · Completed
Key facts
| NCT number | NCT00003840 |
|---|---|
| Title | DTGM Fusion Protein in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia |
| Official title | A Phase I Study of DTGM Fusion Protein (IND BB#8153) in Relapsed and Refractory Adult Acute Myeloid Leukemia (AML) |
| Lead sponsor | Wake Forest University Health Sciences, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Biological |
| Interventions | DTGM fusion protein |
| Start date | Oct 1, 2000 |
| Primary completion | Sep 1, 2002 |
| Completion | Jul 1, 2005 |
| First posted | Apr 12, 2004 |
| Last update posted | Jan 19, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: